An Israeli medical center and cannabis producer are making a joint effort to report weed’s benefits.
Hitting a spliff may just be the best thing for post-traumatic stress disorder (PTSD) next to therapy, according to a recent clinical trial conducted by Soroka University Medical Center and Israeli medical cannabis company Cannbit-Tikun Olam. The study was conducted over several years with the goal of evaluating the safety and efficacy of treatment using medical cannabis.
The results of the trial were considerably positive. Notably, a number of cannabis-medicated patients stopped or reduced their dosages of opioids (by 52%), anti-psychotics (by 36.9%), anti-epileptics (by 35.7%) and hypnotics and sedatives (by 35.3%). Overall, over two thirds of patients reported at least moderate improvement with no serious side effects, with 90.8% of treated PTSD patients being classified as therapeutic successes after six months.
– Read the entire article at The Jeruselam Post.
